文献速递临床试验与 GCP流行病学与生物统计

氢化可的松对严重脓毒症患者休克发生的影响:HYPRESS随机临床试验

Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2016-01-01

HYPRESS双盲随机临床试验纳入380例未发生脓毒性休克的严重脓毒症成人患者,比较氢化可的松与安慰剂对14天内脓毒性休克发生率的影响。结果显示氢化可的松组与安慰剂组脓毒性休克发生率无显著差异(21.2% vs 22.9%,P=.70),结论不支持在此类患者中使用氢化可的松。

要点

  • 严重脓毒症无休克患者中,氢化可的松未降低14天内脓毒性休克风险(21.2% vs 22.9%,P=.70)。
  • 氢化可的松与安慰剂在28天、90天、180天死亡率及ICU/住院死亡率均无显著差异。
  • 氢化可的松组高血糖(90.9% vs 81.5%)和肌肉无力(30.7% vs 23.8%)发生率数值上更高。

核心结论

  • 在未发生脓毒性休克的严重脓毒症成人患者中,与安慰剂相比,氢化可的松未降低14天内脓毒性休克的发生风险。
  • 这些发现不支持在这些患者中使用氢化可的松。

研究设计与样本

  • 双盲随机临床试验,于2009年1月13日至2013年8月27日进行,随访180天至2014年2月23日。
  • 在德国34个大学和社区医院的中级或重症监护病房进行,纳入380例未发生脓毒性休克的严重脓毒症成人患者。
  • 患者按1:1随机分配接受氢化可的松200 mg持续输注5天随后逐渐减量至第11天(n=190)或安慰剂(n=190)。
  • 意向性治疗人群共353例患者(64.9%男性;平均[SD]年龄65.0[14.4]岁)。

主要发现

  • 氢化可的松组170例中36例(21.2%)发生脓毒性休克,安慰剂组170例中39例(22.9%)发生(差异-1.8%;95%CI -10.7%至7.2%;P=.70)。
  • 氢化可的松组与安慰剂组在脓毒性休克发生时间、ICU或住院死亡率方面无显著差异。
  • 28天死亡率:氢化可的松组171例中15例(8.8%)vs 安慰剂组170例中14例(8.2%)(差异0.5%;95%CI -5.6%至6.7%;P=.86)。
  • 90天死亡率:氢化可的松组171例中34例(19.9%)vs 安慰剂组168例中28例(16.7%)(差异3.2%;95%CI -5.1%至11.4%;P=.44)。
  • 180天死亡率:氢化可的松组168例中45例(26.8%)vs 安慰剂组167例中37例(22.2%)(差异4.6%;95%CI -4.6%至13.7%;P=.32)。

关键数值与推荐

  • 主要结局:14天内脓毒性休克发生率,氢化可的松组21.2% vs 安慰剂组22.9%(差异-1.8%;95%CI -10.7%至7.2%;P=.70)。
  • 次要结局:继发感染氢化可的松组21.5% vs 安慰剂组16.9%;脱机失败8.6% vs 8.5%;肌肉无力30.7% vs 23.8%;高血糖(血糖>150 mg/dL)90.9% vs 81.5%。

临床怎么用

  • 原文结论指出这些发现不支持在未发生脓毒性休克的严重脓毒症患者中使用氢化可的松。
  • 原文引言提及拯救脓毒症运动仅建议在难治性脓毒性休克中使用辅助氢化可的松治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Adjunctive hydrocortisone therapy is suggested by the Surviving Sepsis Campaign in refractory septic shock only. The efficacy of hydrocortisone in patients with severe sepsis without shock remains controversial. OBJECTIVE: To determine whether hydrocortisone therapy in patients with severe sepsis prevents the development of septic shock. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, randomized clinical trial conducted from January 13, 2009, to August 27, 2013, with a follow-up of 180 days until February 23, 2014. The trial was performed in 34 intermediate or intensive care units of university and community hospitals in Germany, and it included 380 adult patients with severe sepsis who were not in septic shock. INTERVENTIONS: Patients were randomly allocated 1:1 either to receive a continuous infusion of 200 mg of hydrocortisone for 5 days followed by dose tapering until day 11 (n = 190) or to receive placebo (n = 190). MAIN OUTCOMES AND MEASURES: The primary outcome was development of septic shock within 14 days. Secondary outcomes were time until septic shock, mortality in the intensive care unit or hospital, survival up to 180 days, and assessment of secondary infections, weaning failure, muscle weakness, and hyperglycemia (blood glucose level >150 mg/dL [to convert to millimoles per liter, multiply by 0.0555]). RESULTS: The intention-to-treat population consisted of 353 patients (64.9% male; mean [SD] age, 65.0 [14.4] years). Septic shock occurred in 36 of 170 patients (21.2%) in the hydrocortisone group and 39 of 170 patients (22.9%) in the placebo group (difference, -1.8%; 95% CI, -10.7% to 7.2%; P = .70). No significant differences were observed between the hydrocortisone and placebo groups for time until septic shock; mortality in the intensive care unit or in the hospital; or mortality at 28 days (15 of 171 patients [8.8%] vs 14 of 170 patients [8.2%], respectively; difference, 0.5%; 95% CI, -5.6% to 6.7%; P = .86), 90 days (34 of 171 patients [19.9%] vs 28 of 168 patients [16.7%]; difference, 3.2%; 95% CI, -5.1% to 11.4%; P = .44), and 180 days (45 of 168 patients [26.8%] vs 37 of 167 patients [22.2%], respectively; difference, 4.6%; 95% CI, -4.6% to 13.7%; P = .32). In the hydrocortisone vs placebo groups, 21.5% vs 16.9% had secondary infections, 8.6% vs 8.5% had weaning failure, 30.7% vs 23.8% had muscle weakness, and 90.9% vs 81.5% had hyperglycemia. CONCLUSIONS AND RELEVANCE: Among adults with severe sepsis not in septic shock, use of hydrocortisone compared with placebo did not reduce the risk of septic shock within 14 days. These findings do not support the use of hydrocortisone in these patients. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00670254.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Keh D, Trips E, Marx G, et al. Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial. JAMA. 2016. PMID: 27695824. doi:10.1001/jama.2016.14799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。